Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor

Seth B Coffelt; Karin E de Visser

doi:10.1016/j.immuni.2016.03.014

Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor

Immunity. 2016 Apr 19;44(4):722-4. doi: 10.1016/j.immuni.2016.03.014.

Authors

Seth B Coffelt¹, Karin E de Visser²

Affiliations

¹ Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
² Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address: [email protected].

PMID: 27096314
DOI: 10.1016/j.immuni.2016.03.014

Abstract

Although it is successful for some, most melanoma patients are refractory to T cell checkpoint inhibition. In this issue of Immunity, Merad and colleagues (2016) describe a dendritic-cell-based strategy to heighten the efficacy of therapeutic anti-PD-L1 and BRAF inhibitors in mouse melanoma models.

Publication types

Kommentar

MeSH terms

Animals
B7-H1 Antigen*
Dendritic Cells*
Humans
Melanoma / immunology
T-Lymphocytes / immunology

Substances

B7-H1 Antigen